Hot Stocks

The stock market changes from minute to minute, and what’s hot today may not be hot tomorrow. Our expert analysts spot hot stocks that are heating up before the crowd swoops in to bid prices higher, and our journalists sift through the noise to shine a light on trending investments -- in spaces ranging from quantum computing to marijuana stocks -- to determine whether they’re actually worth your time.

American Airlines’ First Quarter Results Might Not Be Too Bad 

From a revenue and earnings standpoint, American is expected to deliver $9.15 billion and a loss of $2.16 a share in the first quarter. That puts earnings and sales lower by 288% and 19%, respectively, over the fourth quarter and 515% and 14%, respectively, over the first quarter last year.

Up 51% in the Past Month, Does Beyond Meat Have More Upside?

Of the 20 analysts covering Beyond Meat, only four have a buy rating. The rest are either a hold (12), underweight (2), and outright sell (2). As for the analysts’ average 12-month target price, it is $78.89, 21% lower than where Beyond Meat’s stock is currently trading.

Long-Term Bull Amazon May Be Overhyped Ahead of Q1 Earnings

For obvious reasons, Amazon stock has moved significantly higher from the coronavirus pandemic. But with sky-high expectations for grocery delivery sales, AMZN could risk falling short.

Don’t Buy Nokia Stock Before Its Q1 Report

Nokia's first-quarter report will be crucial for Nokia stock. Investors should watch for updates on 5G and the new CEO's performance.

Can Q1 Earnings Help Twitter Lift Out of the Doldrums?

With millions forced to shelter at home, Twitter stock is a natural winner in terms of added viewership. But will this be enough to impress investors ahead of its Q1 earnings report?

Is Exxon Mobil Stock a Bargain?

With everything going on in the world right now, Exxon Mobil stock is on sale. But not all sales are worth buying.

Sure Hilton Closed 1,000 Hotels, but Don’t Jump Ship on Hilton Stock

And while it’s true that Hilton is going to suffer greatly from Covid-19, if one of the world’s largest hotel chains can’t bounce back, I doubt it really matters what happens to the markets; we’ll all be penniless and living in shanty huts.

iQiyi Could Feel the Sting of Investor Lawsuits

IQ stock faces a volatile year with class action lawsuits filed on behalf of investors accusing the Chinese video streaming company of fraud.

Until Trust Is Regained, It’s Best to Avoid CCL Stock

It might be profitable eventually, but holding a position in CCL stock won't be easy. Are you sure you want to sail those choppy seas?

The AbbVie Buyout is Not a Sure Thing for Allergan Stock Investors

The coronavirus has completely changed the narrative on AbbVie’s buyout of AGN. Allergan stock holders banking on it should reconsider.

Now May Be the Time to Take Profits in Qualcomm Stock

Qualcomm stock could face headwinds due to further supply chain and revenue disruptions as the COVID-19 pandemic continues.

Setting the Record Straight on 5G Health Concerns

Some conspiracy theorists are claiming that increased exposure to 5G radiation "lowers immune systems" and makes people more susceptible to the coronavirus. Here's the truth.

What to Expect From TSLA Stock Earnings

Tesla EPS will likely drop back into negative territory in the first quarter, just like it did last year. But TSLA stock bulls will likely continue to buy the stock no matter what numbers the company reports.

Positive Developments for GE Stock Are Mounting

Boeing reopened a key factory and states are allowing hospitals to resume elective surgeries. That's good news for GE stock.

General Electric Stock Will Take Longer to Rebound Than You Think

The best approach to GE stock right now is to wait and see what happens after earnings. There are several headwinds for it to overcome, but you shouldn't completely write it off.

What’s On Tap for 3M Stock With Earnings Just Around the Corner?

3M has been ramping up production of its masks and the rest of the healthcare business should do well too, making MMM stock stand out.

Don’t Let Negative Data Dissuade You from Gilead Sciences

Late last week, a Financial Times report suggested that Gilead’s coronavirus candidate drug remdesivir was not effective. However, the narrative for GILD stock requires a much broader context.

What to Expect From Southwest’s Q1 Earnings Report

LUV stock remains at six-year lows. A lack of consumer demand and uncertain business demand gives investors no reason to buy the stock.

Don’t Count on Real Estate to Save Struggling M Stock

Add in current and future challenges from coronavirus, and M stock could fall to even lower prices. Bottom line: it's best to sit this one out.